![]() |
CiteULike | ![]() |
cmmorel's CiteULike | ![]() |
![]() |
|
![]() |
Register | ![]() |
Log in | ![]() |
Brazil’s Quiet Bio-Medical Innovation Revolution: Drugs, Patents, and the “10/90 Health Research Gap”by: Michael P. Ryan
|
Reviews
[Write a review of this article]
Notes for this article
Find related articles from these CiteULike users
Find related articles with these CiteULike tags
Posting History
AbstractA quiet, little-noticed revolution has been taking place over the past decade in Brazil: With the aim of increasing technology innovation in the marketplace and overcoming debilitating institutional problems, the Brazilian bio-medical innovation system and intellectual property strategy has been substantially reformed. The government has been taking steps to promote technology commercialization by strengthening patent and intellectual property rights, encouraging public-private R&D projects, and providing venture capital to promising initiatives. The fruits of these reforms have begun to ripen as one local drug company released in 2005 Brazil’s first innovative, patent-protected bio-medical product. A first of its kind in strategic R&D alliance between two companies that has established agreements with a number of university collaboration partners is similarly seeking to exploit Brazil’s biodiversity. Its efforts have so far yielded 11 international patents and innovative product potential. The Brazilian bio-medical innovation system, especially if modeled by other bio-diverse developing countries, could contribute new drugs and medical knowledge to diseases of the developing world and thereby alleviate the so-called “10/90 Research Gap.”
BibTeX record
RIS record